Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2023-01-16 Director's Dealing
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by CrystalGenomics regarding their stake in Pangen. This is a standard regulatory filing in South Korea (DART system) used to disclose insider or major shareholder transactions, which falls under the 'Director's Dealing' category as it reports share ownership changes by a major shareholder.
2023-01-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by '화일약품(주)' in '(주)팬젠', including the number of shares, percentage of ownership, and the purpose of the holding (management influence). This type of filing is specifically categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2023-01-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares (646,940 shares, 6.06%) by Hwail Pharmaceutical Co., Ltd. in Pangen Co., Ltd. This type of filing is specifically used to notify the market when a shareholder crosses a significant ownership threshold (typically 5%). In the provided classification schema, 'Major Shareholding Notification' (MRQ) is the correct category for such filings.
2023-01-12 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) held on 2023-01-12. It details the voting outcomes for the appointment of directors and auditors. According to the filing definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the correct category for official results from shareholder votes at any general meeting.
2023-01-12 Korean
최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding a 'Change in Largest Shareholder'. It details the transfer of shares, the identity of the new controlling entity (CrystalGenomics Inc.), the financial impact, and the subsequent appointment of new board members. This type of disclosure is a standard regulatory requirement for public companies to report significant changes in ownership and control, which falls under the 'Regulatory Filings' category.
2023-01-12 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's Chief Executive Officer (CEO). It details the outgoing and incoming representatives, the reason for the change (resignation), and the effective date. This falls directly under the category of board or management changes.
2023-01-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.